Ontology highlight
ABSTRACT:
SUBMITTER: Han TH
PROVIDER: S-EPMC3777854 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature
Han Tae H TH Gopal Ajay K AK Ramchandren Radhakrishnan R Goy Andre A Chen Robert R Matous Jeffrey V JV Cooper Maureen M Grove Laurie E LE Alley Stephen C SC Lynch Carmel M CM O'Connor Owen A OA
Journal of clinical pharmacology 20130610 8
Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells. This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE. Two 21-day cycles of brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies. Each patient also received either a sensitive CYP3A substrate (midazolam), an effecti ...[more]